Form 4: EXAS CEO Conroy Reports Merger-Related Equity Conversion
Merger-Related Insider Transaction Report
Exact Sciences CEO Kevin T. Conroy reported significant changes in his beneficial ownership of company securities following the merger with Abbott Laboratories, converting equity and options into cash.
Summary
- Kevin T. Conroy, President and CEO of Exact Sciences Corp., reported changes in his beneficial ownership due to the merger with Abbott Laboratories, effective March 23, 2026.
- The merger involved Badger Merger Sub I, Inc. (a wholly-owned subsidiary of Abbott) merging into Exact Sciences, with Exact Sciences surviving as a wholly-owned subsidiary of Abbott Laboratories.
- Each outstanding share of Exact Sciences common stock, with certain exceptions, was converted into the right to receive $105.00 in cash (Merger Consideration).
- Conroy disposed of 1,397,738 directly owned common shares, 29,061 shares held in a 401(k) Plan, and 250,715 shares across three Grantor Retained Annuity Trusts, all converted to cash at $105.00 per share.
- On March 23, 2026, 119,312 shares were reported as acquired at a $0 price, representing performance-based restricted stock units (PSUs) that were deemed fully vested based on actual achievement as of November 19, 2025, and subsequently converted into the right to receive $105.00 in cash per share.
- Stock options with exercise prices below the $105.00 Merger Consideration were cancelled and converted into a cash payment based on the difference between the Merger Consideration and the exercise price. This included 235,388 options ($21.68 exercise price), 66,047 options ($44.37), 34,110 options ($92.62), and 100,916 options ($98.18).
- Restricted Stock Units (RSUs) granted before November 19, 2025, were fully vested, cancelled, and converted into the right to receive $105.00 cash per share, totaling 18,143, 44,336, and 83,360 units.
- 154,829 Restricted Stock Units (RSUs) granted on or after November 19, 2025, were assumed by Abbott Laboratories as Parent restricted stock units on substantially the same terms and conditions.
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a highly positive event for the reporting person, Kevin T. Conroy, as it signifies the successful completion of a merger resulting in a substantial cash payout for his equity holdings and options.
Positives
- The merger resulted in a significant cash payout for Kevin T. Conroy's equity holdings and in-the-money stock options at $105.00 per share.
- Performance-based restricted stock units (PSUs) were fully vested and converted to cash.
- Certain restricted stock units (RSUs) were fully vested and converted to cash.
- Other restricted stock units (RSUs) were assumed by Abbott Laboratories, maintaining their value and vesting terms under the new parent company.
Future Outlook
The filing indicates that Restricted Stock Units (RSUs) granted on or after November 19, 2025, were assumed by Abbott Laboratories, implying continued equity participation for some awards under the new parent company.
Industry Context
StockSavvy.ai notes that this Form 4 filing reflects the finalization of a significant acquisition in the diagnostics or healthcare technology sector, where Exact Sciences, a leader in cancer screening and diagnostics, was acquired by a larger diversified healthcare company like Abbott Laboratories. Such mergers often aim to consolidate market share, leverage R&D capabilities, and achieve synergies.
Comparison to Industry Standards
- StockSavvy.ai observes that the cash consideration of $105.00 per share for Exact Sciences common stock and the conversion terms for equity awards are consistent with standard merger agreements in the biotechnology and medical device industries.
- Similar cash-out provisions were seen in the acquisition of Medivation by Pfizer ($14 billion, $81 per share) and the acquisition of Array BioPharma by Pfizer ($11.4 billion, $48 per share), where outstanding equity awards were typically converted to cash or assumed by the acquiring entity.
- The assumption of certain RSUs by Abbott Laboratories is also a common practice to retain key talent post-acquisition, aligning with industry norms for executive compensation in M&A scenarios.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President and CEO | NA | NA | 03/23/2026 | No changes in specific individuals or titles are reported, however, Exact Sciences Corporation became a wholly-owned subsidiary of Abbott Laboratories, which alters the reporting structure and ultimate corporate control for the management team. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Corporate Structure | The merger of Exact Sciences into a wholly-owned subsidiary of Abbott Laboratories fundamentally altered its corporate governance structure, transitioning from an independent publicly traded entity with its own board and committees to being governed under the framework of Abbott Laboratories. | 03/23/2026 | This change eliminates Exact Sciences' independent public company governance, integrating it fully into Abbott's corporate oversight. |
Stakeholder Impact
- Shareholders of Exact Sciences (EXAS) received $105.00 cash per share, representing a liquidity event and the agreed-upon merger consideration.
- Employees of Exact Sciences with equity awards saw them converted to cash or assumed by Abbott, potentially impacting retention and future compensation structures as the company is now part of a larger entity.
- Management, including Kevin T. Conroy, realized significant value from their equity holdings as a result of the merger.
Next Steps
- Continued integration of Exact Sciences into Abbott Laboratories.
- Ongoing management of assumed restricted stock units by Abbott Laboratories.
Key Dates
| Date | Description |
|---|---|
| 02/23/2021 | Date 235,388 stock options became fully exercisable. |
| 02/27/2022 | Date 66,047 stock options became exercisable. |
| 02/26/2023 | Date 34,110 stock options became exercisable. |
| 02/14/2024 | Date 100,916 stock options became exercisable. |
| 02/28/2024 | Original vesting start date for 18,143 RSUs, which were fully vested and converted to cash on March 23, 2026. |
| 02/28/2025 | Original vesting start date for 44,336 RSUs, which were fully vested and converted to cash on March 23, 2026. |
| 11/19/2025 | Date of Agreement and Plan of Merger; date as of which performance conditions for PSUs were deemed satisfied; cut-off date for RSU treatment (before/after). |
| 02/27/2026 | Original vesting start date for 83,360 RSUs, which were fully vested and converted to cash on March 23, 2026. |
| 03/23/2026 | Date of Earliest Transaction; Effective Time of the Merger. |
| 02/25/2027 | Original vesting start date for 154,829 RSUs, which were assumed by Abbott Laboratories as Parent restricted stock units on March 23, 2026. |
Keywords
Exact Sciences, EXAS, Abbott Laboratories, merger, acquisition, Form 4, insider transaction, beneficial ownership, stock options, restricted stock units, PSUs, common stock, Kevin T. Conroy, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.